- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07950462
A Phase 1 Study of QLS7402 Injection in Adult Participants With Overweight or Obesity
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose of QLS7402 Injection Administered Subcutaneously in Adult Participants With Overweight or Obesity
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending dose of QLS7402 injection administered subcutaneously in adult participants with overweight or obesity
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a first-in-human (FIH), randomized, double-blind, placebo-controlled Phase 1 clinical study of QLS7402 injection, which consists of a single ascending dose (SAD) study in adult participants with overweight or obesity. The study is designed to evaluate the safety, tolerability, PK, and PD of QLS7402 following single subcutaneous administration. In accordance with the dose escalation principle, dose escalation will proceed sequentially from the starting dose to higher dose levels. An individual trial participant will receive only one dose level as a single dose. This study is designed with 5 prespecified escalating dose groups.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Qing wen, Master of Medicine
- Numero di telefono: +86-13370551767
- Email: wenq0619@126.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- 1)Willing to participate in this study and provide written informed consent prior to any study-specific procedures; able to understand the study procedures, methods, requirements, and restrictions; and willing to comply with the protocol and complete the study.
- 2) Male and female adults aged between 18 and 55 years, inclusive, at the time of informed consent.
- 3) 27.0 kg/m²≤BMI<35.0 kg/m² at screening.
- 4) Body weight has remained stable for at least 3 months prior to screening(defined as a weight change within ±5%, participant self-reported information is acceptable).
Exclusion Criteria:
- 1) Evidence or history or presence of major diseases, including but not limited to disorders involving the cardiovascular, endocrine (except for primary obesity and mild to moderate hepatic steatosis with normal hepatic function), psychiatric, neurological, gastrointestinal, respiratory, hematological, immunological, urogenital, renal, hepatic, pulmonary, or dermatological systems, or any other condition that, in the judgment of the Investigator, makes the participant unsuitable for this study.
- 2) History of endocrine disorders that may significantly affect body weight (e.g., Cushing's syndrome, hypothalamic obesity, hypothyroidism, or hyperthyroidism), or history of medication-induced obesity, monogenic obesity, or hereditary obesity syndromes.
- 3) History of malignancy.
- 4) Skin conditions and/or tattoos that may interfere with the evaluation of injection site reactions, or abdominal scarring (e.g., due to surgery or burns) that may affect subcutaneous administration; intolerance to subcutaneous injection which, in the investigator's opinion, may preclude study drug administration or local tolerability assessment.
- 5) Difficult venous access (e.g., history of needle phobia or blood phobia), or poor venous conditions that, in the judgment of the Investigator, render the participant unsuitable for enrollment.
- 6) History of or planned any form of bariatric surgery or device-based treatment for obesity during the study period; severe trauma or major surgery within 6 months prior to screening; or planned surgery during the study period.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: QLS7402
QLS7402 Injection |
QLS7402 Injection |
|
Comparatore placebo: Placebo
Placebo Control |
Placebo Control |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Number of participants with treatment-emergent adverse events (TEAEs)
Lasso di tempo: 169 days
|
169 days
|
|
Number of participants with treatment-related adverse events (TRAEs)
Lasso di tempo: 169 days
|
169 days
|
|
Number of participants with serious adverse events (SAEs)
Lasso di tempo: 169 days
|
169 days
|
|
Number of participants with abnormal physical examination, 12-lead ECG and clinical laboratory tests
Lasso di tempo: 169 days
|
169 days
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
The change from baseline in Maximum Plasma Concentration (Cmax)
Lasso di tempo: 3 days
|
3 days
|
|
The change from baseline in Activin E levels
Lasso di tempo: 169 days
|
169 days
|
Collaboratori e investigatori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- QLS7402-101
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .